XPhyto Therapeutic Corporation (XPHYF) Corporate Media Kit

Therapeutics Indication Formulation and development Preclinical study Clinical study Market Pilot Pivotal Rotigotine – TDS Parkinson’s Disease Cannabidiol (CBD) – ODF Epilepsy, other Tetrahydrocannabinol (THC) – ODF Nausea / Anorexia, other CBD:THC combination (1:1) – ODF MS assoc. spasticity, other Pipeline XPhyto Therapeutics Corporation A next generation bioscience company | TDS: transdermal patch; ODF: oral dissolvable film Diagnostics Indication Design and development Feasibility study Final validation CE-Mark Market Rapid RT-PCR COVID-19 Ultra-rapid LFA COVID-19 Peptide biosensor – ODF Infectious disease (multiple) Peptide biosensor – ODF Oral health (multiple) Completed Planned Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q3 2021 Q4 2021 Q4 2021 6 Q2 2021